Abstract: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from neuroendocrine cells, predominantly occurring in the stomach, intestines, pancreas, and lungs. In response to specific targets that arise during the development of NENs, such as somatostatin receptor, C-X-C motif chemokine receptor 4, glucagon-like peptide-1 receptor, fibroblast activation protein, cholecystokinin 2 receptor, researchers have developed a series of PET molecular probes for the diagnosis, tumor staging, treatment guidance, and therapeutic evaluation of NENs. The authors focus on the clinical application and research progress of a series of PET molecular probes specifically targeted at NENs, aiming to clarify the practical value of the probes and facilitate optimal probe selection for individualized management of NENs patients.